Document is current
Any future updates will be listed below
-
Authors
Miyazaki, Takahiro
Maiti, Mekhala
Hennessy, Marlene
Chang, Thomas
Kuo, Peiwen
Addepalli, Murali
Obalapur, Palakshi
Sheibani, Sara
Wilczek, Joanna
Pena, Rhoneil
Quach, Phi
Cetz, Janet
Moffett, Andrew
Tang, Yinyan
Kirk, Peter
Huang, Jicai
Sheng, Dawei
Zhang, Ping
Rubas, Werner
Madakamutil, Loui
Kivimäe, Saul
Zalevsky, Jonathan
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04136756 at ClinicalTrials.govnct04136756 at ClinicalTrials.govDocuments that mention this clinical trial
Circumventing resistance within the Ewing sarcoma microenvironment by combinatorial innate immunotherapy
https://doi.org/10.1136/jitc-2024-009726
NKTR-255, a novel polymer-conjugated rhIL-15 with potent antitumor efficacy
https://doi.org/10.1136/jitc-2020-002024
355 First-in-human phase I study of NKTR-255 in patients with relapsed/refractory hematologic malignancies
https://doi.org/10.1136/jitc-2020-sitc2020.0355
Documents that mention this clinical trial
Circumventing resistance within the Ewing sarcoma microenvironment by combinatorial innate immunotherapy
https://doi.org/10.1136/jitc-2024-009726
NKTR-255, a novel polymer-conjugated rhIL-15 with potent antitumor efficacy
https://doi.org/10.1136/jitc-2020-002024
355 First-in-human phase I study of NKTR-255 in patients with relapsed/refractory hematologic malignancies
https://doi.org/10.1136/jitc-2020-sitc2020.0355
-
Funding
Funding for this research was provided by:
Nektar Therapeutics (Not applicable)
- License Information
